Friday, 18 Jan 2019

You are here

TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk

Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM. Based on a meta-analysis, DM cancer risk is five times higher than in the general population and twice that compared with PM cancer risk. 

Findings from a 2007 analysis of the prevalence of anti-IF1-Ab in IIM cases showed that 50% of anti-TNF1-Ab-positive cases also had cancer-associated myositis (CAM). Additional anti-TIF1-Ab-positive/-negative patients were recruited in this follow-up study of the same cohort up to 10 years. The overall goal was to compare the 10-year cancer risk in anti-TIF-Ab-positive vs –negative DM cases using UKMyoNet data.

Patients were recruited from 74 centers throughout the U.K. Data about demographics and clinical patterns were collected, and all participants had blood samples taken to detect autoantibodies to determine the presence of MSA anti-synthetases (anti-Jo-1, -PL7, -PL12, -EJ, -OJ, -KS, -Zo), other MSAs (anti-TIF1, -Mi-2, -SAE, -SRP, -MDA5, -NXP2, -HMGCR), and MAA (anti-PM-Sci, -Ku, -U1-RNP, -U3-RNP). A total of 55 out of 263 DM cases (21%) were anti-TIF1-Ab positive. The majority were women, and median age at DM diagnosis was 47.

An increased proportion of anti-TIF1-Ab-positive cases developed cancer throughout the study period compared with anti-TIF1-Ab-negative cases (38%) vs (15%). Cancer development in the anti-TIF1-Ab-positive cohort occurred between 3.5 years prior to and 2.5 years after DM onset. While 21 of the anti-TIF1-Ab-positive cases (53%) who were at least 39 years old developed cancer, those matched patients younger than age 39 did not develop cancer over the study period.

In the anti-TIF1 positive group, the most common types of malignancy were breast cancer (33%), ovarian cancer (19%), and lymphoma (14%). In the anti-TIF1 negative group, the most common tumors were breast cancer (25%), lymphoma (13%), and bowel cancer (13%). Ovarian cancer was markedly higher in the anti-TIF1 positive group (19% vs 2%, P<0.05).

Strengths of this study include the large datasets used and long-term detection; however, by definition patients would have had to survive long enough to be recruited into the UKMyoNet. According to the National Institutes of Health, the 2017 European League Against Rheumatism (EULAR) /American College of Rheumatology (ACR) EULAR/ACR classification criteria for adult and juvenile IIM are based on a probability score in which 16 clinical and laboratory features are summed to develop a probability of having an IIM; further sub-classification is needed to identify DM. Since this consensus was only developed recently, there may be inaccuracy in the diagnosis of symptom onset; however, the investigators deemed this to be unlikely, as there was a substantial difference in cancer incidence between the anti-TIF1-Ab-positive and –negative cohorts.

The long-term relationship between anti-TIF1-positive-Ab status and cancer onset was analyzed in this retrospective U.K. study. Patients with DM who were also positive for the anti-TIF1-Ab were at more than threefold increased risk for cancer, the investigators found. In keeping with separate findings, this study identified that the significant association between anti-TIF1-Ab positivity and early cancer diagnosis exists only for those >39 years of age. Anti-TIF1 positive cancer occurred within 3 years either side of the DM onset, and no incident malignancies were detected in this group within the next 7.5 years, whereas cancers were detected during this later period in the anti-TIF1-Ab-negative cases.

Looking for anti-TIF1-Ab in newly diagnosed DM cases could help with the development of a cancer screening plan of action. Previous studies have noted the increased risk for ovarian cancer among women with DM, but this is also the first study to determine that the risk was primarily among the anti-TIF1 positive group, "suggesting that the true association between DM and ovarian cancer may be through possession of anti-TIF1 antibodies. Clinicians should therefore apply increased vigilance for potential ovarian pathology in anti-TIF1 antibody positive cases," the researchers wrote.

"Our findings also strengthen the hypothesis that inflammatory myopathies represent a paraneoplastic reaction initiated by attempted immune-mediated clearance of a cancer," the team concluded.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.

Nailfold Videocapillaroscopy in Dermatomyositis

A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM. 

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma.